Contains Nonbinding Recommendations

Guidance on Glimepiride; Pioglitazone Hydrochloride

Active ingredient: Glimepiride; Pioglitazone Hydrochloride

Form/Route: Tablets/Oral

Recommended studies: 2 studies

1. Type of study: Fasting
   Design: Single-dose, two-way, crossover *in-vivo*
   Strength: 2 mg/ 30 mg
   Subjects: Healthy males and nonpregnant females, general population.
   Additional Comments: To avoid hypoglycemic episodes in healthy volunteers, the drug products should be administered with 240 mL of 20% glucose solution in water. After dosing, 60 mL of 20% glucose solution should be given to each subject every 15 minutes for the following 4 hours.

---

2. Type of study: Fed
   Design: Single-dose, two-way, crossover *in-vivo*
   Strength: 2 mg/ 30 mg
   Subjects: Healthy males and nonpregnant females, general population.
   Additional comments: Please see comments above.

Analytes to measure: Glimepiride and pioglitazone in plasma

Bioequivalence based on (90% CI): Glimepiride and pioglitazone

Waiver request of in-vivo testing: 4 mg/ 30 mg based on (i) acceptable bioequivalence studies on the 2 mg/ 30 mg strength, (ii) acceptable dissolution testing across all strengths, and (iii) proportional similarity in the formulations across all strengths.

Dissolution test method and sampling times:

Please note that a **Dissolution Methods Database** is available to the public at the OGD website at http://www.accessdata.fda.gov/scripts/cder/dissolution/. Please find the dissolution information for this product at this website. Please conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and reference products. Specifications will be determined upon review of the application.